Background We evaluated whether men at risk for death fromprostate cancer after radical prostatectomy can be identifiedusing information available at diagnosis.
Methods We studied 1095 men with localized prostate cancer toassess whether the rate of rise in the prostate-specific antigen(PSA) level — the PSA velocity — during the yearbefore diagnosis, the PSA level at diagnosis, the Gleason score,and the clinical tumor stage could predict the time to deathfrom prostate cancer and death from any cause after radicalprostatectomy.
From Brigham and Women's Hospital and Dana–Farber Cancer Institute, Boston (A.V.D.); the Department of Radiation Oncology, Harvard Medical School, Boston (A.V.D.); the Department of Statistics, University of Connecticut, Storrs (M.-H.C.); the Department of Psychiatry, Washington University School of Medicine, St. Louis (K.A.R.); and the Department of Urology, Northwestern Feinberg School of Medicine, Chicago (W.J.C.).
Address reprint requests to Dr. D'Amico at the Department of Radiation Oncology L-2 Level, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at adamico{at}lroc.harvard.edu.
PSA Velocity and Prostate Cancer
Dodd L. E., Simon R., Bianco F. J. Jr., Kattan M. W., Scardino P. T., D'Amico A. V., Chen M.-H., Catalona W. J.
Extract |
Full Text |
PDF
N Engl J Med 2004;
351:1800-1802, Oct 21, 2004.
Correspondence
This article has been cited by other articles:
Vollmer, R. T.
(2010). Dissecting the Dynamics of Serum Prostate-Specific Antigen. Am J Clin Pathol
133: 187-193
[Abstract][Full Text]
Wo, J. Y., Chen, M.-H., Nguyen, P. L., Renshaw, A. A., Loffredo, M. J., Kantoff, P. W., D'Amico, A. V.
(2009). Evaluating the Combined Effect of Comorbidity and Prostate-Specific Antigen Kinetics on the Risk of Death in Men After Prostate-Specific Antigen Recurrence. JCO
27: 6000-6005
[Abstract][Full Text]
de Crevoisier, R., Slimane, K., Messai, T., Wibault, P., Eschwege, F., Bossi, A., Koscielny, S., Bridier, A., Massard, C., Fizazi, K.
(2009). Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy. Ann Oncol
0: mdp365v1-mdp365
[Abstract][Full Text]
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J. Jr, Yossepowitch, O., Vickers, A. J., Klein, E. A., Wood, D. P., Scardino, P. T.
(2009). Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. JCO
27: 4300-4305
[Abstract][Full Text]
O'Brien, M. F., Cronin, A. M., Fearn, P. A., Smith, B., Stasi, J., Guillonneau, B., Scardino, P. T., Eastham, J. A., Vickers, A. J., Lilja, H.
(2009). Pretreatment Prostate-Specific Antigen (PSA) Velocity and Doubling Time Are Associated With Outcome but Neither Improves Prediction of Outcome Beyond Pretreatment PSA Alone in Patients Treated With Radical Prostatectomy. JCO
27: 3591-3597
[Abstract][Full Text]
BICKERS, B., AUKIM-HASTIE, C.
(2009). New Molecular Biomarkers for the Prognosis and Management of Prostate Cancer - The Post PSA Era. Anticancer Res
29: 3289-3298
[Abstract][Full Text]
Arneth, B. M.
(2009). Clinical Significance of Measuring Prostate-Specific Antigen. Lab Med
40: 487-491
[Abstract][Full Text]
Cooperberg, M. R., Broering, J. M., Carroll, P. R.
(2009). Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. JNCI J Natl Cancer Inst
101: 878-887
[Abstract][Full Text]
Vickers, A. J., Savage, C., O'Brien, M. F., Lilja, H.
(2009). Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer. JCO
27: 398-403
[Abstract][Full Text]
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R. C. Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P.
(2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin. Chem.
54: e11-e79
[Abstract][Full Text]
Jansen, F. H., Roobol, M., Bangma, C. H., van Schaik, R. H. N.
(2008). Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection. Clin. Chem.
54: 1999-2006
[Abstract][Full Text]
Stein, W. D., Figg, W. D., Dahut, W., Stein, A. D., Hoshen, M. B., Price, D., Bates, S. E., Fojo, T.
(2008). Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data. The Oncologist
13: 1046-1054
[Abstract][Full Text]
Mucci, L. A., Pawitan, Y., Demichelis, F., Fall, K., Stark, J. R., Adami, H.-O., Andersson, S.-O., Andren, O., Eisenstein, A., Holmberg, L., Huang, W., Kantoff, P. W., Kim, R., Perner, S., Stampfer, M. J., Johansson, J.-E., Rubin, M. A.
(2008). Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol. Biomarkers Prev.
17: 1682-1688
[Abstract][Full Text]
Thuret, R., Massard, C., Gross-Goupil, M., Escudier, B., Di Palma, M., Bossi, A., de Crevoisier, R., Chauchereau, A., Fizazi, K.
(2008). The postchemotherapy PSA surge syndrome. Ann Oncol
19: 1308-1311
[Abstract][Full Text]
Barry, M. J., Kaufman, D. S., Wu, C.-L.
(2008). Case 15-2008 -- A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer. NEJM
358: 2161-2168
[Full Text]
Schlom, J., Gulley, J. L., Arlen, P. M.
(2008). Paradigm Shifts in Cancer Vaccine Therapy. Exp Biol Med
233: 522-534
[Abstract][Full Text]
Nepple, K. G., Joudi, F. N., Hillis, S. L., Wahls, T. L.
(2008). Prevalence of Delayed Clinician Response to Elevated Prostate-Specific Antigen Values. Mayo Clin Proc.
83: 439-445
[Abstract][Full Text]
Loeb, S., Catalona, W. J.
(2008). What to Do with an Abnormal PSA Test. The Oncologist
13: 299-305
[Abstract][Full Text]
Ulmert, D., Serio, A. M., O'Brien, M. F., Becker, C., Eastham, J. A., Scardino, P. T., Bjork, T., Berglund, G., Vickers, A. J., Lilja, H.
(2008). Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population. JCO
26: 835-841
[Abstract][Full Text]
Kakehi, Y., Kamoto, T., Shiraishi, T., Ogawa, O., Suzukamo, Y., Fukuhara, S., Saito, Y., Tobisu, K.-i., Kakizoe, T., Shibata, T., Fukuda, H., Akakura, K., Suzuki, H., Shinohara, N., Egawa, S., Irie, A., Sato, T., Maeda, O., Meguro, N., Sumiyoshi, Y., Suzuki, T., Shimizu, N., Arai, Y., Terai, A., Kato, T., Habuchi, T., Fujimoto, H., Niwakawa, M.
(2008). Prospective Evaluation of Selection Criteria for Active Surveillance in Japanese Patients with Stage T1cN0M0 Prostate Cancer. Jpn J Clin Oncol
0: hym161v1-7
[Abstract][Full Text]
Mucci, L. A., Pawitan, Y., Demichelis, F., Fall, K., Stark, J. R., Adami, H.-O., Andersson, S.-O., Andren, O., Eisenstein, A. S., Holmberg, L., Huang, W., Kantoff, P. W., Perner, S., Stampfer, M. J., Johansson, J.-E., Rubin, M. A.
(2008). Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort. Cancer Epidemiol. Biomarkers Prev.
17: 249-251
[Abstract][Full Text]
Walsh, P. C., DeWeese, T. L., Eisenberger, M. A.
(2007). Localized Prostate Cancer. NEJM
357: 2696-2705
[Full Text]
Xiao, Z., Halls, S., Dickey, D., Tulip, J., Moore, R. B.
(2007). Fractionated versus Standard Continuous Light Delivery in Interstitial Photodynamic Therapy of Dunning Prostate Carcinomas. Clin. Cancer Res.
13: 7496-7505
[Abstract][Full Text]
Banez, L. L., Hamilton, R. J., Partin, A. W., Vollmer, R. T., Sun, L., Rodriguez, C., Wang, Y., Terris, M. K., Aronson, W. J., Presti, J. C. Jr, Kane, C. J., Amling, C. L., Moul, J. W., Freedland, S. J.
(2007). Obesity-Related Plasma Hemodilution and PSA Concentration Among Men With Prostate Cancer. JAMA
298: 2275-2280
[Abstract][Full Text]
Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C. O., de Wit, R., Tannock, I. F., Eisenberger, M.
(2007). A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. Clin. Cancer Res.
13: 6396-6403
[Abstract][Full Text]
Etzioni, R. D., Ankerst, D. P., Weiss, N. S., Inoue, L. Y. T., Thompson, I. M.
(2007). Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence. JNCI J Natl Cancer Inst
99: 1510-1515
[Abstract][Full Text]
Schlom, J., Arlen, P. M., Gulley, J. L.
(2007). Cancer Vaccines: Moving Beyond Current Paradigms. Clin. Cancer Res.
13: 3776-3782
[Abstract][Full Text]
Fall, K., Garmo, H., Andren, O., Bill-Axelson, A., Adolfsson, J., Adami, H.-O., Johansson, J.-E., Holmberg, L.
(2007). Prostate-Specific Antigen Levels as a Predictor of Lethal Prostate Cancer. JNCI J Natl Cancer Inst
99: 526-532
[Abstract][Full Text]
Albertsen, P. C.
(2006). PSA Testing: Public Policy or Private Penchant?. JAMA
296: 2371-2373
[Full Text]
Bloom, J. R., Stewart, S. L., Oakley-Girvans, I., Banks, P. J., Chang, S.
(2006). Family History, Perceived Risk, and Prostate Cancer Screening among African American Men.. Cancer Epidemiol. Biomarkers Prev.
15: 2167-2173
[Abstract][Full Text]
Carter, H. B., Ferrucci, L., Kettermann, A., Landis, P., Wright, E. J., Epstein, J. I., Trock, B. J., Metter, E. J.
(2006). Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.. JNCI J Natl Cancer Inst
98: 1521-1527
[Abstract][Full Text]
Smellie, W S A, Forth, J, Sundar, S, Kalu, E, McNulty, C A M, Sherriff, E, Watson, I D, Croucher, C, Reynolds, T M, Carey, P J
(2006). Best practice in primary care pathology: review 4. J. Clin. Pathol.
59: 893-902
[Abstract][Full Text]
Miller, D. C., Gruber, S. B., Hollenbeck, B. K., Montie, J. E., Wei, J. T.
(2006). Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.. JNCI J Natl Cancer Inst
98: 1134-1141
[Abstract][Full Text]
Hanley, R., Rieger-Christ, K. M., Canes, D., Emara, N. R., Shuber, A. P., Boynton, K. A., Libertino, J. A., Summerhayes, I. C.
(2006). DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer. Clin. Cancer Res.
12: 4569-4574
[Abstract][Full Text]
Carter, H. B.
(2006). Assessing risk: does this patient have prostate cancer?. JNCI J Natl Cancer Inst
98: 506-507
[Full Text]
Catalona, W. J., Loeb, S., Han, M.
(2006). Viewpoint: expanding prostate cancer screening.. ANN INTERN MED
144: 441-443
[Abstract][Full Text]
Kadkol, S. S., Lin, A. Y., Barak, V., Kalickman, I., Leach, L., Valyi-Nagy, K., Majumdar, D., Setty, S., Maniotis, A. J., Folberg, R., Pe'er, J.
(2006). Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.. IOVS
47: 802-806
[Abstract][Full Text]
Cooperberg, M. R., Moul, J. W., Carroll, P. R.
(2005). The Changing Face of Prostate Cancer. JCO
23: 8146-8151
[Abstract][Full Text]
Klotz, L.
(2005). Active Surveillance for Prostate Cancer: For Whom?. JCO
23: 8165-8169
[Abstract][Full Text]
Lee, A. K., D'Amico, A. V.
(2005). Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy. JCO
23: 8192-8197
[Abstract][Full Text]
Kadoch, C., D'Amico, A. V., Matthews, R. H.
(2005). When Prostate Brachytherapy Fails: A Case Report and Discussion. The Oncologist
10: 799-805
[Abstract][Full Text]
Sheffield, J. V.L., Larson, E. B.
(2005). Update in General Internal Medicine. ANN INTERN MED
143: 212-221
[Full Text]
D'Amico, A. V., Chen, M.-H., Roehl, K. A., Catalona, W. J.
(2005). Identifying Patients at Risk for Significant Versus Clinically Insignificant Postoperative Prostate-Specific Antigen Failure. JCO
23: 4975-4979
[Abstract][Full Text]
Temple, R. J.
(2005). Enrichment Designs: Efficiency in Development of Cancer Treatments. JCO
23: 4838-4839
[Full Text]
D'Amico, A. V., Renshaw, A. A., Sussman, B., Chen, M.-H.
(2005). Pretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy. JAMA
294: 440-447
[Abstract][Full Text]
Anscher, M. S.
(2005). PSA Kinetics and Risk of Death From Prostate Cancer: In Search of the Holy Grail of Surrogate End Points. JAMA
294: 493-494
[Full Text]
Dotan, Z. A, Bianco, F. J. Jr, Rabbani, F., Eastham, J. A., Fearn, P., Scher, H. I., Kelly, K. W., Chen, H.-N., Schoder, H., Hricak, H., Scardino, P. T., Kattan, M. W.
(2005). Pattern of Prostate-Specific Antigen (PSA) Failure Dictates the Probability of a Positive Bone Scan in Patients With an Increasing PSA After Radical Prostatectomy. JCO
23: 1962-1968
[Abstract][Full Text]
Dodd, L. E., Simon, R., Bianco, F. J. Jr., Kattan, M. W., Scardino, P. T., D'Amico, A. V., Chen, M.-H., Catalona, W. J.
(2004). PSA Velocity and Prostate Cancer. NEJM
351: 1800-1802
[Full Text]
Alibhai, S. M.H.
(2004). What is the prevalence of prostate cancer among men with low prostate-specific antigen levels?. CMAJ
171: 572-572
[Full Text]
(2004). PSA Velocity Predicts Prostate Cancer Outcomes. JWatch General
2004: 1-1
[Full Text]
Eisenberger, M., Partin, A.
(2004). Progress toward Identifying Aggressive Prostate Cancer. NEJM
351: 180-181
[Full Text]
Previous
